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Summary 
Recent studies have investigated how defined peptides influence T  cell development. Using a 
T  cell receptor-transgenic [32-microglobulin--deficient  model, we have examined T  cell matu- 
ration in fetal thymic organ cultures in the presence of various peptides containing single-ala- 
nine substitutions of the strong peptide agonist, p33.  Cocultivation with the peptide A4Y, 
which contains an altered T  cell contact residue, resulted in efficient positive selection. Several 
in vitro assays demonstrated that A4Y was a moderate agonist relative to p33. Although A4Y 
promoted positive selection over a wide concentration range, high doses of this peptide could 
not induce clonal deletion. Thymocytes maturing in the presence of A4Y were no longer able 
to respond to A4Y, but could proliferate against p33. These studies demonstrate that (a) pep- 
tides that induce eflficient positive selection at high concentrations are not exclusively antago- 
nists; (b) some agonists do not promote clonal deletion; (c) positive selection requires a unique 
T  cell  receptor-peptide-major  histocompatibility complex interaction;  and  (d)  interactions 
with selecting peptides during T cell ontogeny may define the functional reactivity of mature T 
cells. 
T 
CRs expressed on maturing thymocytes interact with 
peptide-MHC complexes on thymic stromal cells and 
transmit signals  that lead to either positive or negative T 
cell selection (1-3).  Positive selection is an active process 
that  rescues  self-MHC-restricted  thymocytes  from  pro- 
grammed cell death. In contrast, negative selection tolerizes 
potentially autoreactive T  cells, either through clonal dele- 
tion or unresponsiveness.  Clonal deletion physically removes 
thymocytes by inducing apoptosis,  as compared with unre- 
sponsiveness, which modifies developing T cells so that they 
can no longer respond against the tolerizing antigen. Since 
positive and negative selection shape the TCR repertoire 
and define the basis  of self-/non-self-antigens, much re- 
search has focused on understanding T  cell development. 
Studies have addressed how clonotypic TCRs expressed on 
CD4+CD8 +  double-positive  thymocytes can  distinguish 
between these two selection events. Although it has been 
demonstrated  that peptides  are  involved in  positive  and 
negative selection (4,  5),  it remains controversial whether 
the selecting ligand has a qualitative or quantitative role in 
determining the fate of the developing T cell. 
Recently, altered peptide  ligands  have been  identified 
that can inhibit some or all mature T cell effector functions 
(6-10).  Antagonist peptides are defined as ligands that en- 
gage TCRs and actively inhibit biological responses.  Partial 
agonists  are closely related peptides that stimulate a subset 
ofT cell effector functions (11). This is in contrast with ag- 
onist peptides, which induce a complete range ofT cell re- 
sponses.  Studies by Hogquist et al. (12,  13) and Jameson et 
al.  (14) showed a correlation between peptide antagonists 
and positive selection. These results suggest that a positively 
selecting peptide  is  qualitatively different from a  peptide 
agonist and that the selecting ligand shares features charac- 
teristic of partial agonists  and antagonists. However, other 
studies have demonstrated that low concentrations of a strong 
peptide  agonist  can  promote  positive  selection,  whereas 
higher concentrations of the same peptide lead to negative 
selection (15, 16), suggesting that quantitative differences in 
thymocyte-stromal cell  interactions determine the fate of 
the maturing T cell. 
The nature of the selecting ligand has direct implications 
on the type of signals generated during thymocyte selection 
and has fostered several models ofT cell development (17- 
22).  Recent  experiments  have  demonstrated that altered 
peptide ligands generate a different ratio ofintracellular sig- 
nals compared with agonist-induced T  cell activation (23, 
24).  These biochemical alterations support the hypothesis 
that  a  positively selecting  antagonist peptide  transmits  a 
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maturation.  For instance,  a  selecting ligand may induce  a 
specific TCR  conformation  that  conveys  a  partial signal, 
resulting in  positive selection  (3).  Models  supporting  the 
correlation between incomplete signals generated by antag- 
onists or partial agonists and positive selection are based on 
the inability of these peptides to activate mature T  cells. It 
is equally feasible that selecting peptides simply contribute 
to the affinity of TCR-MHC  interactions and do not pos- 
sess  novel  signaling properties.  In  an  attempt  to  address 
these various issues, we have examined how minor changes 
of a natural peptide ligand alter TCR-transgenic thymocyte 
selection. 
T  cell development was  examined using a  TCR-trans- 
genic  mouse  model  (327  line)  specific  for  lymphocytic 
choriomeningitis virus  glycoprotein peptide  (LCMV-gp) 1 
presented by the MHC class I molecule, H-2D  b. TCR-trans- 
genic 132-microglobulin (~2m) deficient (TCR J32m  -/-) mice 
were  generated,  and  fetal  thymic  lobes  from  these  mice 
were cultured in the presence of exogenous ~2m and vari- 
ous peptides containing single alanine substitutions of the 
strong  peptide  agonist  p33.  Our  results  describe  a  novel 
peptide agonist capable of inducing positive selection but 
not clonal deletion. This selection process seems to involve 
a unique  TCR-peptide-MHC  engagement that is not re- 
stricted to  agonist or antagonist peptides. In addition, our 
data demonstrate  that  the  interactions between  TCR  and 
peptide-MHC  during  development modify the  reactivity 
and the ability of the mature  T  cell to respond to foreign 
peptide antigens. 
Materials and Methods 
Mice.  TCR-transgenic mice were previously generated using 
ot and [3 chains isolated from CTL clone P14, which recognized 
the LCMV  glycoprotein (peptide p33-41)  presented by H-2D  b 
(25).  This line was crossed with H-2  b [32  m-/- mice (26).  TCR- 
transgenic F 1 mice were subsequently backcrossed with ~2  m-/- 
mice to obtain TCR [32m  -/- (H-2  b) mice. Progeny were typed 
for transgenic TCR and homozygous [32m disruption by staining 
peripheral blood with mAbs at 4~  in PBS containing 2% FCS, 
0.2% NAN3, and 20 mM EDTA. TCR-transgenic cells were de- 
tected with rat anti-mouse V[38.1 (KJ16) mAb (27) followed by 
FITC-conjugated goat anti-rat mAb (Tago Inc., Burlingame, CA). 
f32m -/-  mice were screened for a lack of CD8 + cells using rat 
anti-mouse CD8 (YTS 169.4)  mAb (28) followed by FITC-con- 
jugated goat anti-rat mAb. After the second Ab incubation pe- 
riod, RBC were lysed using 1￿  FACS  |  lysing solution (Becton 
Dickinson & Co., Mountain View, CA). TCR + RAG2 -/- mice 
were previously generated (29). 
Fetal Thymic Organ Cultures  (FTOC).  Timed breedings were 
established between TCR [32  m-/- H-2  b males and [32m  -/- H-2  b 
females.  At day 16 of gestation, females were killed, and thymic 
lobes were removed from the fetuses.  DNA was extracted from 
embryonic tails so that transgenic fetuses could be determined us- 
ing primers  (V~x2 -  CTG  ACC  TGC  AGT TAT  GAG GAC 
I Abbreviatons used in this paper: Av, adenovirus; [32m, [~2-microglobulin; 
FTOC, fetal thymic organ culture; HSA, heat stable antigen; LCMV-gp, 
lymphocytic choriomeningitis virus glycoprotein peptide. 
AGC AC and Cot  -  CGA GGA TCC  TTT  AAC TGG TAC 
ACA GCA GG) specific for the Vet2 TCR transgene. The fetal 
thymic lobes were placed on 0.8-I.Lm polycarbonate filters (Costar 
Corp., Cambridge, MA), which floated on  1 ml of IMDM,  1￿ 
Nutridoma-SP (Boehringer Mannheim Corp., Indianapolis, IN), 
5  ￿  10 -5 M  2-ME, penicillin, streptomycin, 2 mM glutamine, 
2.5  ~g human 132m (Sigma Chemical Co., St. Louis, MO), and 
designated peptides. These lobes were  then  cultured for 6  d  at 
37~  during which time the medium was changed daily. After 
this incubation period, the  thymic lobes were  teased apart and 
stained with mAbs at 4~  in PBS containing 2% FCS and 0.2% 
NaN  3.  Three-color analysis was done with rat anti-mouse PE- 
conjugated anti-CD4 (Cedarlane Laboratories Ltd., Homby, On- 
tario, Canada), FITC-conjugated anti-CD8 (Cedarlane Laborato- 
ries Ltd.), and biotinylated anti-Vot2  (B20.1)  (PharMingen,  San 
Diego, CA), or biotinylated anti-heat stable antigen (HSA) (M1/ 
69)  (PharMingen).  Biotinylated antibodies were  detected with 
streptavidin-red 670 (GIBCO BRL, Gaithersburg, MD). 
Flow Cytometry.  All flow cytometric analysis was performed 
on a FACScan  |  instrument (Becton Dickinson & Co.). Samples 
were gated for live cells based on forward and side scatter param- 
eters (10,000 events/sample) and analyzed using Lysys II software 
(Becton Dickinson & Co.). 
Peptides.  The  peptides  p33  (KAVYNFATM),  A4Y  (KA- 
VANFATM),  AIK  (AAVYNFATM),  A3V  (KAAYNFATM), 
A6F (KAVYNAATM), A8T  (KAVYNFAAM), S4Y  (KAVSN- 
FATM), adenovirus peptide AV (SGPSNTPPEI), and LCMV nu- 
cleoprotein 118-127  (RPQASGVYMG)  were  synthesized by a 
solid-phase method using the Fmoc/tBu-based protocol. Chain 
assembly was carried out at the Amgen Institute using a single- 
coupling program on an ABI-431 instrument. The crude prod- 
ucts were purified on a reverse-phase preparative HPLC column 
(C4; Vydac, Hesperia, CA). Homogeneity of the final products 
was assessed by analytical HPLC.  Characterization was provided 
by amino acid analysis and electrospray mass spectometry. 
Peptide Modeling.  H-2D  b models of p33 and A4Y were mod- 
eled using both published (30) and unpublished (Thomson, C.T., 
S.G. Nathenson,  and J.C.  Sacchettini, unpublished data) H-2D  b 
crystal structure coordinates with initial results obtained using the 
homology module of Insight II software programs from Biosym 
Technologies (San Diego, CA). Models were refined for  1,000 
cycles of steepest descents energy minimization. 
Peptide-bindingAssay.  In  peptide-pulsing  experiments,  10  ~' 
RMA-S cells, which were previously cultured overnight at 29~ 
in RPMI plus 10% FCS, were incubated with various concentra- 
tions of peptide at 29~  for 30 min. These cells were then trans- 
ferred to  a  37~  incubator for 3  h,  after which the  cells were 
washed and stained with anti-H-2D  b mAb from tissue culture su- 
pernatant (B22.249)  (31, 32) and then FITC-conjugated rat anti- 
mouse  Ig (Sigma Chemical Co.).  RMA-S cells were incubated 
with LCMV nucleoprotein 118-127 (H-2  d restricted) (33) to de- 
termine background H-2D  b expression. 
CytolyticAssay.  MC57G  fibroblast target  cells  (H-2  b)  were 
prepulsed with peptides (10 -6 M) for 3 h at 37~  and pulsed with 
51Cr (Dupont NEN,  Boston, MA) for 1 h  at 37~  These cells 
(104/well) were then incubated for 5 h at 37~  in 96-well round- 
bottom plates with  serial dilutions of spleen cells  from  TCR- 
transgenic mice that had been primed intravenously 4  d  earlier 
with 5 ￿  10  6 PFU LCMV-Armstrong. The supernatant was sub- 
sequently counted using a  gamma counter  (model  1282  Com- 
pugamma CS Universal; LKB Wallac, Turku, Finland). The per- 
centage of specific lysis was calculated as (experimental release - 
spontaneous release)/(total release -  spontaneous release)  ￿  100. 
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<20% in all experiments. 
Primary In  Vitro Generation of Cytotoxicity.  TCR-transgenic 
spleen  cells  (3  ￿  106/well)  were  cocultured  with  irradiated 
C57B1/6J macrophages coated with p33, A4Y, or AV (10 -6, 10 -s 
or 10 -~~ M) at 37~  in IMDM, 10% FCS, 5 ￿  -s 2-ME, peni- 
cillin, and streptomycin. 3  d  later these cultures were harvested 
and  incubated  with  EL-4  target  cells  (H-2  u)  that  had  been 
prepulsed with peptides (10 -6 or 10 -8 M) for 3 h and pulsed with 
SlCr (Dupont NEN)  for 1 h  at 37~  Peptide-specific lysis was 
determined using a standard 5-h chromium release assay. Sponta- 
neous release from peptide-coated EL-4 target cells was <20% in 
all cases. 
Proliferation Assays.  Spleen cells (105/well) from TCR-trans- 
genic or TCR.-transgenic RAG2 -/- mice were incubated in trip- 
licate in 96-well flat-bottom plates with 2  ￿  104/well irradiated 
C57B1/6J  (H-2  b) macrophages that had been prepulsed with vari- 
ous concentrations of peptide for 3 h at 37~  After 48 h of co- 
cultivation, the cells were pulsed with 1 I~Ci of [3H]-thymidine 
(Amersham Corp., Arlington Heights,  IL) for  16  h.  Cells were 
harvested and counted on a direct beta counter (Matrix96; Can- 
berra Packard Canada Ltd., Mississauga,  Ontario, Canada). 
GM-CSF/IL-3Assay.  Supernatant  from  TCR-transgenic 
spleen cells (10S/well) cocultured with irradiated, peptide-coated 
C57B1/6J  (H-2  b)  macrophages was  collected and transferred to 
96-well flat-bottom microtiter plates containing washed FDC-P1 
cells  (104/well)  that had not received fresh medium containing 
IL-3 for 3-4 d. The cells were incubated for 24 h and then pulsed 
with 1 I~Ci of [3H]-thymidine for 16 h at 37~  Cells were har- 
vested and counted on a Matrix96 direct beta counter. A standard 
curve was generated using serial dilutions of recombinant mouse 
IL-3 (Genzyme Corp., Cambridge, MA). 
TCR Antagonist Assay.  Irradiated C57B1/6J  macrophages (2 ￿ 
104/well) were prepulsed with 10 -8 M p33 for 3 h at 37~  after 
which the cells were washed three times and pulsed with serial di- 
lutions of A4Y or S4Y (KAVSNFATM). These cells were incu- 
bated for another 3  h  at 37~  washed, and then cultured with 
TCR-transgenic spleen cells (10S/weE)  at 37~  for 48 h.  These 
cultures were then pulsed with 1 IxCi of [3Hl-thymidine for 16 h, 
after  which  time  the  cells  were  harvested  and  counted  on  a 
Matrix96 direct beta counter. 
FTOC Proliferation Assay.  Cultured thymic lobes were teased 
apart and stained at 4~  in PBS containing 2% FCS with FITC- 
conjugated anti-CD8 (Cedarlane Laboratories Ltd.) and PE-con- 
jugated anti-CD4 (Cedarlane Laboratories Ltd.). These cells were 
then sorted using a FACStar  |  Plus instrument (Becton Dickinson 
& Co.) to collect CD8 + thymocytes. Irradiated spleen cells from a 
C57B1/6J  mouse were prepulsed with 10 -8 M  AV, A4Y, or p33 
for 3 h at 37~  washed, and distributed in triplicate on a flat-bot- 
tom 96-well plate at a concentration of 105 cells/well. CD8 + thy- 
mocytes (3  ￿  104/well) resuspended in IMDM,  10% FCS, peni- 
cillin, streptomycin, and 5  ￿  -s M  2-ME were then added to 
these wells. The cells were cultured at 37~  for 4 d, pulsed with 
1 IxCi of [3H]-thymidine for 16 h, and harvested as described. 
Results 
A  Modified  Peptide  Containing  a  Single  Alanine  Substitution 
Mediates Efficient Positive Selection.  To  examine  how  pep- 
tides influence thymocyte selection, fetal thymic lobes from 
TCtL [32  m-/-  mice were cultured in the presence of 132m 
and various peptides containing a single alanine substitution 
of the strong peptide agonist, p33  (KAVYNFATM).  One 
of the peptide variants, A4Y (KAVANFATM), was notable 
for its ability to efficiently induce TCP,-transgenic thymocyte 
maturation. This was characterized by a skewed CD8 + pop- 
ulation that expressed high levels of the transgenic TCtk as 
demonstrated by three color flow cytometry (Fig. 1 a). When 
TCR  [32m  -/-  fetal thymic  lobes were  incubated in vitro 
with  exogenous  J32m, few CD8 +  cells were  detected, and 
these cells did not express high levels of the transgenic re- 
ceptor. A  control adenovirus (AV) peptide (SGPSNTPPEI), 
which is known to efficiently bind to H-2D  b (34, 35)  also 
did not  induce  maturation  of the  LCMV-specific TCR hi 
thymocytes. Three-color analysis of positively selected TCIk  hi 
thymocytes demonstrated that CD8 + thymocytes expressed 
low levels of liSA, characteristic of mature thymocytes (36) 
(Fig. 1 b). As shown in Table 1, A4Y generated four to five 
times as many CD8 §  thymocytes compared with negative 
control FTOCs.  In  addition,  the  majority of CD8 +  thy- 
mocytes collected from AV-treated organ  cultures stained 
HSA  hi,  indicating that  these  cells had  not  yet undergone 
positive selection (data not shown). These experiments dem- 
onstrate that the peptide A4Y positively selected the trans- 
genic  TCR  with  an  efficiency  comparable  to  wild-type 
TCR. 132  m+ lobes cultured in media alone. Therefore, pos- 
itive selection of the transgenic TCP,, is efficiently mediated 
by the altered peptide antigen A4Y. 
Alterations  at  Position  4  Potentially  Affects  a  TCR  Contact 
Residue.  To  characterize  this  peptide,  molecular models 
of A4Y and p33 bound in the groove of H-2D b (30) were 
generated and compared. Based on the peptide sequences, 
it was predicted that the tyrosine amino acid side chain at 
position 4 was directed away from the MHC  class I mole- 
cule and interacted with the TCR. (Fig. 2 a). This is consis- 
tent with  evidence from in vivo studies of variant LCMV 
Table 1.  Total and CD8 + Thymocyte Numbers from TCR 
f12  m-l- and TCR r  +/§ FTOCs Treated with  Various Peptides 
Peptide  Total cell number"  CD8 + cell number* 
TCR 132  m-/- (n =  4) 
No peptide  7.5 +- 0.8 ￿  10  s  6.0 +- 0.6 ￿  104* 
AV (10 -6 M)  5.8 +- 0.7 ￿  l0  s  5.2 ~+ 0.6 X  104, 
A4Y (10 -6 M)  7.8 -+ 0.3 ￿  10 s  2.3 +  0.1  ￿  105 
TCR 13~m  -/- (n =  5) 
A4Y (10 .4 M)  7.2 -+ 1.4  ￿  10  s  2.2 +- 0.4 ￿  105 
A4Y (10 -6 M)  6.3 +- 1.2 X  10  s  2.4 -  0.4 ￿  10  s 
A4Y (10 -9 M)  6.1  +  0.8 ￿  10 s  1.7  _+ 0.2 ￿  105 
TCR [32  m+/+ (n =  8) 
No peptide  1.2 +  0.3 ￿  106  3.2 +- 0.8 ￿  105 
A4Y (10 .6 M)  9.0 +- 3.0 ￿  105  2.2 --- 0.7 X  10  s 
p33 (10 .6 M)  1.0 --0.2 ￿  10 s  1.0 -+ 0.2 ￿  104 
*Data _+ SD. 
*  Predominantly immature CD8 + HSA  hi thymocytes. 
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Figure 1.  Addition of A4Y results in efficient positive selection of transgenic thymocytes in TCtL ~2  m-/- FTOC. (a) Three-color analysis of TCIL 
132m  -/- thymic lobes cultured without peptide, AV (a control H-2Db-restricted  adenovirus peptide) or A4Y were stained with antibodies specific for 
CD4, CD8, and Vct2. CD8 + cells were gated, and the profiles of Vee2 expression are shown. This experiment was repeated 10 times, producing similar 
results. (b) TCtL ~2m  +/+ and TCIL 132m  -/- fetal thymic lobes cultured with A4Y were stained with antibodies specific for CD4, CD8, and HSA. HSA 
profiles are shown from gated CD4+CD8 + or CD8 + cells. These data are representative of four separate experiments. 
strains  isolated  from  TCR-transgenic  mice.  These  virus 
variants escape  the  immune  surveillance of the  transgenic 
TCR  by altering the p33-41  epitope  at positions 3  and 4 
(37).  Therefore,  the  alanine substitution at this position is 
predicted to affect TCR-peptide  interactions. 
Previous  experiments  have  shown  that  asparagine  and 
methionine are  anchor  residues  that  bind to  H-2D b  (38). 
Although  these  amino  acids  were  not  modified  in  A4Y, 
peptide  binding to  H-2D b  was  tested  using  the  murine 
lymphoma cell line RMA-S  (39).  RMA-S  cells incubated 
with  various  concentrations of p33,  A4Y,  or  control  AV 
showed similar increases in H-2D b staining (Fig. 2  b), dem- 
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Figure  2.  Peptide  A4Y  con- 
tains an alanine substitution that 
is likely to affect a TCR contact 
residue.  (a)  The  peptides  A4Y 
and p33 are shown as modeled in 
the binding groove of an H-2D  b 
molecule (side view). The TC1L 
contact residues are oriented to- 
ward the top of the page. (Figure 
produced  by  MOLSCRIPT). 
(b) The ability ofpeptides to res- 
cue H-2D  b surface expression on 
RMA-S  cells  was  characterized 
by  percentage  increase in  mean 
fluorescence relative to the con- 
trol  peptide,  LCMV nucieopro- 
rein  118-127  (H-2  a  restricted) 
(33).  RMA-S cells were treated with different concentrations of p33 (11), 
A4Y (@), or AV (&). Similar results were obtained when this experiment 
was repeated four times. 
onstrating that these peptides have a comparable ability to 
bind to the MHC class I molecule. 
The Peptide A4Y Displays Agonistic Properties.  The  abil- 
ity of the transgenic TCtL to interact with A4Y and p33 
was  compared  in  several  in  vitro  assays. To  determine 
whether the transgenic TCIL could recognize A4Y, TCIL 
[32  m+  mice were immunized  with LCMV,  and  activated 
spleen  cells  were incubated with  target  cells  pulsed  with 
p33, A4Y, or an irrelevant adenovirus peptide AV (Fig. 3). 
Comparable specific lysis was seen in the presence of  targets 
100- 
80- 
C/J 
_~6o- 
0 
~40- 
o~ 
20- 
90  30  10  3 
Effector/Target Ratio 
Figure  3.  Activated  TCIL- 
tramgenic T  cells recognize  the 
peptides p33  and A4Y.  The cy- 
totoxic  activity  of  LCMV- 
primed  transgenic  T  cells  was 
tested  against target  cells  coated 
with p33  (11), A4Y  (@),  or AV 
(&).  These  data  are  representa- 
tive  of CTL  analysis from  four 
mice. 
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coated with p33 or A4Y, showing that the activated tmns- 
genic T  cells could easily recognize both peptides. 
This cytotoxic assay addresses  the ability of activated T 
cells to recognize the altered peptides, but does not exam- 
ine whether these peptides can directly activate the trans- 
genic T  cell population.  For this reason,  TCtk-transgenic 
spleen cells  from naive mice were cocultured with mac- 
rophages coated with different concentrations (10  -6,  10  -s 
or 10  -1~ M) of the peptides p33, A4Y, and AV. After 3 d, 
serial dilutions of each well were incubated with target cells 
coated with  10  ~6 or  10  -s  M  p33,  A4Y,  or AV  (Fig.  4). 
Comparable cytolytic activity specific for p33 or A4Y was 
detected using transgenic T  cells  previously cultured with 
p33.  The percentage of cytotoxicity was  slightly reduced 
when activated in the presence of macrophages pulsed with 
low  concentrations of p33  peptide  (10  -1~ M).  However, 
transgenic T  cells  cocultivated in  the presence of various 
concentrations of A4Y were only able to weakly lyse tar- 
gets expressing either p33 or A4Y. No specific lysis was de- 
tected using control cultures incubated with irrelevant pep- 
fide. Visual examination of cells cultured under these various 
conditions suggested that strong proliferation only occurred 
in the wells containing the peptide p33. These experiments 
show that both p33 and A4Y can initiate cytotoxic effector 
functions. However, the relatively limited cytotoxic response 
induced by A4Y-primed T  cells  suggests  that this peptide 
did not interact with the transgenic TCtL as efficiently as 
the wild-type peptide. 
It is possible that A4Y  could not induce optimal cyto- 
toxicity because of a reduced ability to trigger the prohfera- 
tion of naive transgenic T  cells. Therefore, prohferation as- 
says were done by cocultivating transgenic spleen cells with 
macrophages pulsed with various concentrations of differ- 
ent peptides (Fig.  5 a). A significantly stronger proliferative 
response was detected from T  cells cultured in the presence 
of p33  compared with  A4Y.  Interestingly, A4Y  induced 
similar levels of T  cell activation relative to other alanine- 
substituted variants of p33  that were less efficient at pro- 
moting transgenic thymocyte maturation. 
To confirm that these in vitro observations were specific 
for the transgenic TCtL and not due to the expression of 
endogenous TCR-et chains, we performed a prohferation 
assay using splenocytes from TCtL RAG2 -/- mice. Since 
these  T  cells  do not express endogenous TCtk-et chains, 
Fig. 5 b verifies that the observed results were in fact due to 
the  transgenic  TCtL.  These  experiments show  that  A4Y 
can  ehcit a  TCtL-transgenic prohferative response,  albeit 
not to the same extent as p33. 
Cytokine  assays were  performed to  further investigate 
A4Y's ability to stimulate TCtk-transgenic T  cell effector 
functions.  As  shown  in  Fig.  6,  A4Y  could induce  GM- 
CSF/IL-3 production. Cytokine levels were reduced when 
compared with  supernatant from p33-stimulated cultures; 
however, this reduction paralleled the previously observed 
decrease in  prohferation. T  cells  cultured  with  a  control 
peptide did not produce detectable levels of IL-3. Similar 
results  were  found  when  IL-2  production  was  analyzed 
(data  not  shown).  This work  demonstrates  that  A4Y  in- O3 
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G  tt 
1  ~.  C  .,'  =  7.  ~-  C"  =  =  - 
27  1  3  9  27  1  3  9  27 
Dilution  of Responder Cultures 
Figure 4.  Primary in vitro generation ofcytotoxicity 
demonstrates that the A4Y agonist has a reduced ability 
to  interact  with  the  transgenic TCR.  The  cytotoxic 
activity of naive transgenic T  cells cultured  with p33 
(A-C), A4Y (D-F), or AV (G-/) at concentrations of 
10 -6 (A, D, and G),  10  -s (B, E, and H), or 10  -m M 
(C,  F, and /) were  incubated  with target cells coated 
with  10  -6 or  10  -8 M  (solid and open symbols, respec- 
tively) p33 (11), A4Y (O), or AV (&). 
a 
60- 
50- 
E 
Q. 
O 
O 
30-  r 
.o_ 
~ 20- 
s 
Q-IO- 
0 
Peptide concentration  (10  -x M) 
Figure  5.  The peptide A4Y can 
activate mature T cells and induce 
reduced  proliferation  relative  to 
p33. (a) The proliferative response 
of mature spleen cells from TCR- 
transgenic  mice  was  measured 
when stimulated with macrophages 
pulsed with various concentrations 
of p33  (ml) or the alanine-substi- 
tuted variants A1K (A), A3V (O), 
A4Y(F]), A6F  (*),  or A8T  (0). 
Background  proliferation  for  T 
cells incubated  with macrophages 
coated with AV peptide  was  600 
cpm Similar results were obtained 
when  this  experiment  was  re- 
peated  three  times.  (b) TCR-spe- 
cific proliferation was assayed using 
TCR + RAG  ./. splenocytes stim- 
ulated with macrophages that were 
prepulsed with  10  s M  p33  (solid 
bar), A4Y (white bar), or AV (shaded bar). Background  proliferation was 
2,000 cpm. Repetition of this experiment produced similar results. 
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duces a similar range ofT  cell effector functions as the strong 
peptide agonist, p33, and that the only noticeable difference 
is in the magnitude of the response. 
A4Y  Is Not an Antagonist Peptide.  To  ensure  that  A4Y 
did  not have  any antagonistic properties,  this peptide  was 
tested for its ability to inhibit transgenic T  cell proliferation 
in  the  presence  of  the  strong  agonist  peptide,  p33.  As 
shown in Fig. 7, the altered peptide S4Y was able to inhibit 
p33-induced T  cell proliferation over a wide range of con- 
centrations in  a  dose-dependent  manner,  characteristic  of 
an antagonist peptide.  In contrast,  A4Y  did not inhibit T 
cell proliferation at  any concentration tested.  Instead,  this 
peptide  displayed  a  synergistic  effect  with  p33  in a  dose- 
dependent manner. Since A4Y can activate T  cells, induce 
effector functions, and does not demonstrate any properties 
associated with peptide antagonists, these experiments sug- 
gest that A4Y is a moderate agonist. 
Different  Concentrations  of A 4Y Induce  Positive  Selection  but 
Not  Clonal Deletion of the  Transgenic  TCR.  To  determine 
whether different concentrations of A4Y could induce pos- 
itive or negative selection, TCR  [32  m-/-  fetal thymic lobes 
were  cultured over a wide range of peptide concentrations 
(Fig. 8  a). TCR  132m  -/-  thymic lobes cultured in the pres- 
ence  of 10-4-10 -9  M  A4Y  led to  efficient maturation of 
33%  (---  7%,  n  =  20)  CD8 +  TCP, +  thymocytes.  Lower 
concentrations  of A4Y  did  not  affect  transgenic  TCR'- 
thymocyte maturation. Interestingly, clonal deletion could 
not be induced at any concentration using A4Y. 
Previous  reports  have  suggested  that  the  density  of the 
MHC  molecules on the cell surface contribute to the over- 
all  avidity  that  influences  selection  events  in  the  thymus 
(12,  40,  41).  Therefore,  TCR  132m  +/+  thymic lobes were 
cocultured with p33  or A4Y to  determine whether  donal 
deletion could be induced in the presence of"normal" lev- 
Positively Selecting Peptide Agonist F, 
5  6  7  8  9  10  11 
Peptide concentration  (10  x M) 
Figure  6.  The  peptide  ago- 
nists p33  and  A4Y both induce 
GM-CSF/IL-3  production. 
GM-CSF/IL-3 production from 
TCR-transgenic  spleen  cells 
stimulated  with  peptide-coated 
macrophages was measured after 
24 h  of cocuhivation. The APC 
were previously pulsed with var- 
ious  concentrations of p33  (11), 
A4Y  (O),  or AV  (A).  This  ex- 
periment  was  repeated  twice, 
producing similar results. 
els  of class I  expression.  As  expected,  CD8 +  thymocytes 
expressed high levels of Vow2 in the absence of exogenous 
peptide (Fig. 8 b). A similar phenotype was observed in the 
presence of 10  -6 M  A4Y.  In contrast, cocultivation in the 
presence of 10 -6 M  p33 led to reduced fetal thymic lobe 
cellularity and a few immature CD8  + ceils expressing low 
levels of VoL2. Thus A4Y does not induce efficient clonal 
deletion of thymocytes expressing the transgenic TCR in 
[~2m  +/+  thymic lobes. 
Functional  Specificity of TCR-transgenic  Thymocytes  Is  Al- 
tered in the Presence of  A4Y.  To examine whether the thy- 
mocytes that mature in fetal organ culture were tolerant or 
responsive to the peptide that promoted positive selection, 
proliferation  assays were  done.  CD8 +  thymocytes  from 
TCR 13zm  + thymic lobes selected in the presence of A4Y 
and TCR ~3zm  -/-  thymic lobes were incubated with APC 
that were pulsed with p33, A4Y, or AV (Fig. 9). Although 
TCR  132m  +  thymocytes proliferated in  response  to  both 
A4Y and p33, thymocytes positively selected by A4Y could 
only mount a comparable proliferative response against p33. 
These results demonstrate that the functional specificity of 
thymocytes expressing the same TCR is altered depending 
on the selecting peptide. 
Discussion 
Properties of Positively Selecting Peptides.  Using  fetal  thy- 
mic organ cultures, a variety of different peptides have been 
Figure 7.  A4Y is not a peptide 
antagonist  for  the  transgenic 
TCK.  Transgenic  T  cell prolif- 
eration  in  response  to  APC 
prepulsed with 10  -8 M  p33 was 
assayed  in  the  presence  or  ab- 
sence of the indicated peptides. 
Background  profiferation  was 
1,000  cpm.  Five  other  similar 
experiments yielded comparable 
results.  (solid  bar,  A4Y;  light 
shaded bar, S4Y;  dark shaded bar, 
p33). 
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directly implicated in  thymocyte selection.  More specifi- 
cally, antagonists,  partial agonists,  and strong peptide ago- 
nists  have been shown to promote T  cell maturation. Be- 
cause  these  peptides  have  strikingly  different  effects  on 
mature T  cells, the significance of these ligands during thy- 
mocyte ontogeny has  remained  controversial.  In  one in- 
stance, a strong agonist was shown to induce both positive 
and  negative selection at  different peptide  concentrations 
(15,  16), suggesting that altered TCl~-peptide-MHC avid- 
ity determined the fate of maturing T  cells.  On the other 
hand, it was found that high concentrations of peptide an- 
tagonists could induce positive selection (12,  13), implying 
that  an  altered  TCP,-peptide-MHC  interaction  was  re- 
quired for thymocyte maturation. Current experiments us- 
ing the peptide A4Y suggest that the correlation between 
antagonists or partial agonists  and positive selection is coin- 
cidental. A4Y is clearly an agonist since it can activate naive 
transgenic T  cells and induce T  cell effector functions. At 
the same time, this peptide can positively select thymocytes 
over a large concentration range, including the high pep- 
tide concentrations required for antagonist peptides.  Since 
A4Y induces T  cell effector functions and does not demon- 
strate any properties characteristic of a peptide antagonist, 
this work shows that agonists  are capable of mediating pos- 
itive selection. More importantly, agonists can promote thy- 
mocyte maturation at peptide concentrations that activate 
mature T  cells in vitro. 
Thymocyte  Tolerance.  Our studies have shown that high 
concentrations of  A4Y (10  -4 M) cannot induce clonal dele- 
tion of transgenic T  cells in TCR [~2  m-/-  and TCR ~2m  +/+ 
fetal thymic  organ  cultures  (Fig.  8  and  data not  shown). 
However, transgenic T  cells that were positively selected in 
the  presence of A4Y  were unable to respond against this 
agonist in proliferation assays, in spite of the fact that these 
mature T  cells  could mount a response against  the strong 
peptide agonist, p33. Therefore, these data suggest that trans- 
genic thymocytes are not clonally deleted but rendered tol- 
erant to A4Y. 
Interactions in the thymus that lead to clonal unrespon- 
siveness  have not been well defined. Models using Mls-1 ~ 
suggest that T cells become unresponsive when tolerogen is 
presented in  suboptimal  conditions  (42,  43),  or when  T 
cells are unable to efficiently interact with Mls-P (29,  44). 
These experiments argue that relatively less efficient TCIL 
interactions lead to reduced T  cell stimulation and result in 
unresponsiveness instead of deletion (45).  This interpreta- 
tion is consistent with our findings. Since A4Y cannot in- 
duce as strong a proliferative response as p33, this suggests 
that A4Y cannot engage the transgenic TCR as efficiently, 
and as a result cannot induce clonal deletion in FTOC. 
Previous studies examining interactions that lead to clonal 
deletion have shown that antigens capable of activating ma- 
ture  T  cells  can  clonally delete these  thymocytes during 
ontogeny (46-49).  Further studies have demonstrated that 
even antigens that are unable to activate peripheral T  cells 
expressing a defined TCR can induce TCR-specific thy- 
mocyte clonal deletion (50,  51).  In addition,  experiments 
have shown that less antigen is required for clonal deletion a  CD8 § 
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A4Y (10  6  M) 
TCRI?,2m § 
p33  (10  4  M) 
Figure  8.  The peptide A4Y induces positive 
selection but not ctonal deletion of TCP~  + thy- 
mocytes. (a) TCR (32  m-j- fetal thymocytes were 
positively selected over a wide range of A4Y pep- 
tide  concentrations.  These  thyrmc  lobes  were 
cultured  with  different concentrations  of A4Y 
and analyzed with  antibodies specific for CD4, 
CD8, and V~t2. The data shown are firom 1 ex- 
periment representative of 10. (b) TCR [~2  m+ fe- 
tal thymocytes were cultured in media alone or 
high concentrations of A4Y or p33. Thymocytes 
from these lobes were then  analyzed with anti- 
bodies specific for CD4,  CD8,  and Va2.  Vc~2 
profiles of CD8 + cells are shown. After gating for 
CD4- thymocytes, CD8 expression was also de- 
termined.  The  mean  fluorescence  of  the 
CD4-CD8+-gated cells is displayed. Similar re- 
sults were obtained when this experiment was re- 
peated five times. 
than T  cell activation (52, 53).  One interpretation of these 
studies has been that the requisite interactions for clonal de- 
letion of thymocytes are less stringent than those required 
for T  cell activation. This hypothesis is attractive because it 
ensures that T  cells with potential self-reactivity are elimi- 
nated during ontogeny, and consequently autoimmunity is 
avoided in the periphery. 
Nonetheless,  our results conflict with this view of thy- 
mocyte tolerance. Although A4Y can stimulate naive trans- 
genic T  cell effector functions, this peptide does not induce 
clonal  deletion  when  cocultured  with  TCR  ~2m -/-  or 
TCP, l~2m  §  thymic lobes. It is possible that the avidity of 
thymocyte---stromal cell  interactions  dictates  the  form  of 
negative selection imposed on the developing T  cell. High 
avidity interactions lead to clonal deletion, whereas lower 
avidity interactions result in unresponsiveness.  In this case, 
interactions with  A4Y  do  not  surpass an  avidity required 
for clonal deletion. Instead,  the transgenic thymocytes are 
positively selected and modified by the selecting hgand so 
that they no longer respond against A4Y. 
Previous studies have shown that coreceptor downregu- 
ladon may be one of the mechanisms used by thymocytes 
1100  T Cell Reactivity Altered by Positively Selecting Peptide Agonist Figure  9.  TCR +  thymocytes 
selected in the presence of A4Y 
are  tolerant to the positively se- 
lecring ligand  bm proliferate  in 
response to  p33.  TCI~  +  CD8 + 
thymocytes from TCtL  [32m  -t- 
thymic lobes cultured with A4Y 
(solid bars) or TCR fl2m  § thymic 
lobes  cultured  in  media  alone 
(shaded  bars)  were  cocultured 
with peptide-coated APC. Back- 
ground proliferation for TCK T 
cells cultured with macrophages 
in  the  absence  of peptide  was 
200 cpm. These results are repre- 
sentative of  five experiments. 
to compensate for high affinity TCK interactions (13,  54, 
55),  resulting in  unresponsiveness instead of clonal dele- 
tion. In our present experiments, analysis of TCR+CD8 + 
thymocytes maturing in the presence of  A4Y did not show 
altered CD8 levels when compared with T cells from TC1L 
[32m  + thymic lobes (Fig. 8 b). However, it is possible  that 
other molecules contributing to the overall avidity ofT cell 
interactions have been altered. 
Alternatively, thymocyte selection  may induce  a  bio- 
chemical change in the developing T  cell, resulting in un- 
responsiveness  to defined ligands.  Our findings suggest that 
peptides capable  of mediating positive selection imprint a 
"resting threshold" or a "resting state" on these thymocytes. 
As a consequence, the T  cells become unresponsive to fur- 
ther encounters with the positively selecting peptide. Thy- 
mocyte modification during positive selection establishes a 
mechanism for preventing peripheral autoimmunity. Previ- 
ous experiments have shown that thymic epithelium is ca- 
pable  of mediating positive  (56) and  negative  selection 
(57-60). Therefore, it is possible  that positive selection and 
thymocyte modification leading to unresponsiveness both 
occur during interactions with the thymic epithelium. How- 
ever, in our model system it is not possible  to determine 
whether tolerance to A4Y is imprinted by the thymic epi- 
thehum or during further interactions with bone marrow- 
derived cells. 
A recent study addressed the role of agonists during thy- 
mocyte maturation by using an ovalbumin peptide and strong 
agonist variants of  this epitope in TCR [32  m-/- FTOC (14). 
Although the strong agonist variant could stimulate TCK  + 
CD8 + phenotypic maturation, these T  cells could not re- 
spond against ovalbumin as measured by proliferation as- 
says. For this  reason,  the  authors  concluded that  agonist 
peptides  cannot  mediate  positive  selection  of functional 
CD8 §  T  cells.  However, the present work  demonstrates 
that agonists can indeed produce mature CD8 + T  cells and 
that these cells are functional. In our model, mature thy- 
mocytes are  rendered tolerant toward positively selecting 
ligands,  and they are  predicted  to  respond  against unde- 
fined, higher affinity peptides (29). This prediction is sup- 
ported by recent experiments that have demonstrated that a 
given T cell receptor can respond against a variety ofepitopes 
that contain unrelated peptide sequences  (61, 62). This sug- 
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gests that high affinity peptides may be totally unrelated to 
the  positively selecting ligand.  In the  case  of ovalbumm 
variants that possess strong agonist properties, it is possible 
that assays testing TCR+CD8 +  T  cell function have not 
used peptides exhibiting high enough affinity to surpass the 
defined resting threshold. We believe that a subset of ago- 
nist peptides cart induce thymocyte differentiation and func- 
tional reactivity while maintaining tolerance to selecting pep- 
tides. 
Models of Thymocyte  Selection.  Models of thymocyte de- 
velopment have to explain how a  TCk  can discriminate 
between a positively and negatively selecting ligand. In ad- 
dition, these hypotheses must incorporate current data dem- 
onstrating the contribution ofpeptides during these events. 
To this extent, recent experiments have favored an efficacy 
model ofT cell maturation (18). In this case, efficacy is de- 
fined as the ability of a hgand to catalyze TC1k-mediated 
biological activity. According to this model, a certain TCR- 
peptide-MHC affinity threshold must be surpassed in order 
for a thymocyte to be eligible for positive  selection.  Ligands 
that meet these criteria can potentially determine whether 
positive or negative selection occurs. Peptides that are un- 
able to initiate T  cell activation are predicted to promote 
positive selection. In contrast, peptides that are capable  of 
provoking receptor-mediated activity (efficacy) induce nega- 
tive selection. If this model is correct, then antagonist pep- 
tides, which according to this hypothesis have no efficacy, 
should positively select,  and peptide agonists, which have 
high  efficacy, should  negatively select  maturing T  cells. 
Studies by Hogquist et al. (12,  13) and Jameson et al. (14) 
support this hypothesis. However, current experiments us- 
ing A4Y demonstrates that an agonist capable  of inducing 
TCR-mediated activity can  positively select thymocytes. 
These findings conflict with a simple efficacy model ofthy- 
mocyte selection. 
A  related developmental model postulates that positive 
selection is the result of incomplete TCR signaling (3, 22). 
This hypothesis proposes that extensive TCR-peptide-MHC 
cross-hnking without suitable conformational change gen- 
erates incomplete signaling and lack ofT cell activation. An- 
tagonist peptides have been postulated to interact with T 
cells in such a manner and induce positive selection. In ad- 
dition, induction of conformational change without exten- 
sive cross-linking would provide too weak a signal to acti- 
vate thymocytes, thus providing an explanation as to how 
low concentrations of agonist peptides such as p33  posi- 
tively select.  Frequent binding of activating agonist pep- 
tides would result in tonal deletion. However, current ex- 
periments are not consistent with this model. Instead, high 
concentrations of A4Y,  which should induce an agonist- 
like conformational change, positively selects transgenic  thy- 
mocytes. Therefore, a conformational model that relies on 
incomplete TCR signaling to induce positive selection can- 
not explain current results. 
Alternatively, these data may be interpreted in terms of 
an affinity/avidity model of T  cell  maturation (17).  Like 
the efficacy hypothesis, this model assumes that a thymocyte 
must have adequate avidity for peptide-MHC to be posi- tively  selected.  However,  an  affnity/avidity  model  does 
not limit positively selecting ligands to antagonist or partial 
agonist  peptides.  For  instance,  different  concentrations  of 
A4Y, ranging from 10 -9 to 10 -4 M, can interact with trans- 
genic  TCRs  and  provide  suffcient  stimulation  to  induce 
positive selection.  However, if the only role of a positively 
selecting peptide  is to  contribute  to  TCR-peptide-MHC 
affinity, then other peptides with the ability to induce simi- 
lar  T  cell  responses  should  promote  similar levels  of thy- 
mocyte maturation, This does not seem to be the case. Ala- 
nine-substituted variants of the wild-type peptide that produce 
comparable levels of proliferation relative to A4Y (Fig. 5 a) 
were not nearly as eflficient as A4Y at promoting transgenic 
T  cell maturation.  Although the affinity between the TCR 
and ligands has not been directly measured, our results sug- 
gest that A4Y has an undefined,  intrinsic  capacity to posi- 
tively select transgenic thymocytes that cannot be fully ex- 
plained using an affnity/avidity model. 
If positively selecting peptides  have an intrinsic  quality, 
then  current  experiments  demonstrate  that this  attribute  is 
not confined to antagonists  or partial agonists.  There is no 
direct  correlation  between  a  peptide's  ability to  positively 
select thymocytes and its ability to activate mature T  cells. 
Instead, our data suggest that positively selecting ligands are 
made up of a distinct subset ofpeptides that are able to gen- 
erate unique interactions with the TCR. Peptides that meet 
a basic requirement,  be it a distinct conformational change 
or a novel form of TCR  stimulation,  positively select thy- 
mocytes. In addition,  experiments using various concentra- 
tions of the high affnity peptide p33 show that there must 
be some signaling gradient that directly or indirectly reflects 
thymocyte--stromal cell avidity. For this reason, we propose 
that peptides  that are capable of unique  TCR  interactions 
induce  positive  selection.  Thymocytes  that  are  positively 
selected by these peptides  are modified  such  that they  re- 
main tolerant against these ligands. This "resting threshold" 
may also be altered during intermediate avidity interactions 
that are independent  of positive selection  (29).  However to 
maintain  this  resting  threshold,  continual  TCR-peptide/ 
MHC  interactions may be required.  Higher avidity interac- 
tions  push  these  thymocytes  toward  clonal  deletion.  As  a 
result,  mature  T  cells  that  have  undergone  this  selection 
process are unresponsive  to self-peptides encountered  dur- 
ing development and yet are capable of responding  against 
higher affnity foreign peptides in the periphery. 
Although  previous  models  have  incorporated  ideas  of 
dynamic T  cell reactivity and variable activation thresholds 
(63,  64),  these concepts have not been supported  by solid 
experimental  evidence.  Our  results  suggest  that  a  T  cell's 
"resting state" is fine tuned during positive and negative se- 
lection  events in the  thymus.  It remains to be determined 
whether  this  process  involves  modification  of thymocyte 
avidity or modulation of an intrinsic biochemical pathway. 
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